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A growing number of young people (YP) are requesting predictive testing
(PT) for Huntington’s disease (HD), yet there is little research in this area.
The aim of this study was to explore YP’s experiences of PT for HD, the
impact of their result and any gaps in information or support. In-depth
interviews were conducted with YP who sought PT for HD from nationally
funded Genetics Services. Participants were recruited through the Grampian
Genetics Service or Scottish Huntington’s Association. Twelve female
participants aged 17–26 years were recruited (seven below 20 years).
Pre- and post-test interviews were conducted where possible. A qualitative
thematic analysis suggests three main testing experiences, regardless of test
result. Testing may be: (i) a journey of empowerment, (ii) an ambivalent
process or (iii) a poor experience. In pre-test counselling, gaps in emotional
support were highlighted. The post-test period was particularly difficult if
there were unanticipated changes in family dynamics or an individual’s
result contradicted what they expected ‘deep down’. YP’s experiences of PT
for HD are generally similar to those of adults, but testing may help or
interfere with key issues related to this age and stage. Implications for
clinical practice are outlined.
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Huntington’s disease (HD) is an autosomal domi-
nant neurodegenerative disorder with onset classically
between 35 and 55 years (1). Symptoms include cog-
nitive impairment, movement disorder, personality and
behavioural changes (1). Life expectancy is approxi-
mately 15–20 years from the onset. There remains no
cure but there are guidelines for Standards of Care (2).
Children of an affected or a gene-positive parent have a
50% risk of inheriting the mutation and developing the
illness in later life.
Predictive testing (PT) has been available for adults
at risk for more than two decades. Nevertheless, less
than 25% of those at risk present for PT, ranging from
3% to 25% in published reports (3). Testing often brings
psychological and social challenges, but also benefits
such as relief of uncertainty, information to make future
plans and reproductive choices (4). In 1994, an interna-
tional PT protocol was developed to outline best clinical
practice to protect those at risk. These guidelines have
recently been updated to take into account the findings
from two decades of psychosocial research (5). Impor-
tantly, PT for HD has not led to increased rates of suicide
or psychiatric illness (4). And whilst carriers may experi-
ence initial shock and upset they generally adjust to their
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result within 1 year, although anxiety levels may rise in
the long term (4). Nevertheless, PT for HD can have a
far-reaching impact, with reactions only partially depen-
dent on the outcome (4). And whilst non-carriers express
relief some have difficulties adjusting to a good result (6).
Although the numbers of those who test remain low the
age of those testing may be changing. For example, in the
UK, there has been an increase in YP aged 20 years and
belowwho test (7). Concerns have been raised about test-
ing YP because it may domore harm than good (8). Thus,
one consistent recommendation is that the minimum age
of testing be 18 years, although minors who seek testing
should have access to genetic counselling (5).
The little research which has been undertaken into
YP’s experiences (those aged 16–25 years) suggests
that the benefits and harms of testing are similar to
adults’, and that the majority adjust and do not regret
their decision (9–12), but these findings are based on
small retrospective samples, usually from one genetics
centre with the majority of participants receiving a
‘good’ result. In online forums, some YP have reported
traumatic testing experiences (13), supporting studies
which suggest that the process itself can engender harms
and benefits (10, 12).
Little research has explored the extent to which testing
impacts on developmental tasks of this life stage (10)
and it is not known if YP have different information
and support needs from adults (11). The aim of this
study was to explore YP’s prospective and retrospective
experiences of PT for HD, the impact of their result and




Participants were recruited through the Grampian Genet-
ics Service and the Scottish Huntington’s Association
(SHA) between August 2011 and November 2013. Any
new or previous test candidate aged 25 years and below
was invited to take part by the consultant (n= 11) or SHA
(n= 13). Potential participants were asked to send back a
reply slip to the researcher (K. F. K.). Purposive sampling
was used to recruit as diverse a range of participants as
possible (14). After an explanation about the study, all
participants were asked to sign a written consent form
agreeing to take part.
The study was approved by the North of Scotland
Research Ethics Service.
Data collection
Semi-structured interviews were conducted (by K. F.
K.) with the majority of participants and lasted between
30 and 90 mins. Interviews took place in participants’
homes or the genetic clinic. One participant chose to be
interviewed by phone and another by e-mail. Prospec-
tive and retrospective interviews were conducted where
possible. All phone and in-person interviews were audio-
taped with consent and fully transcribed; confidentiality
and anonymity were assured.
The interviews focussed on: reasons for seeking PT,
experiences of the testing process, the impact of any
result, any gaps in information or support, as well as par-
ticipants’ experiences of HD. One interview was stopped
because of the participant’s distress. Post-interview sup-
port was arranged with a health professional.
Data analysis and presentation
The analysis was conducted in two main phases. In the
initial phase, a thematic analysis was undertaken using
a system of open coding and the constant comparison
method (15, 16). K. F. K. identified themes and categories
by reading and re-reading transcripts. Different segments
of the data were then grouped together into separate
categories, allowing reflection on the major themes and
any relationships among them. The thematic analysis
was ongoing throughout the fieldwork until a point of
data saturation was reached about the main themes (16).
In the later phase, the findings were also interpreted
with reference to existing psychological and social
theory, where issues related to adolescent development
(17), family systems (18) and (dis)empowerment (19)
were anticipated to arise. Thus, whilst phase 1 aimed to
generate inductive themes from participants’ accounts,
phase 2 interpreted these accounts within a broader
theoretical framework.
To illustrate the range and complexity of participants’
experiences, we present five case studies for discussion.
These cases have been chosen because they illustrate the
main themes and categories within the whole dataset.
The participants
Twenty-four patients were invited to participate by the
clinical geneticist (8 females and 3 males) or SHA (13
females). Fourteen replied and 12 were interviewed (2
were lost to follow-up). Six were recruited by the clinical
geneticist and six through the SHA.
Ten participants were tested, one withdrew and the
remaining participant was lost to follow-up. Seven
participants took part in pre- and post-test interviews,
two only in pre-test and three in retrospective inter-
views. Two partners were also interviewed but were not
included in the analysis.
Table 1 summarises participant demographic charac-
teristics. All participants were female and described their
ethnicity as ‘white.’ All names and identifiable details
have been changed to protect confidentiality.
Results
Our qualitative analysis found that testing was expe-
rienced by YP as either: (i) a journey of empower-
ment (n= 3), (ii) an ambivalent process (n= 4), or (iii)
a poor experience (n= 5), regardless of test results.
Four categories structured each account: Family back-
ground, Deciding to test or not, Experience of Pre-test
Counselling and Post-Testing/Postponing testing. The
length of testing was typical for the UK for nine partici-
pants – varying from between 5 to 9 months (7).
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Table 1. Demographic characteristics of patients interviewed
Age
Mean age 21 years (range 17–26)
Adolescents aged 17–19=7
Young adults aged 24–26= 5
Number of participants
Married or living with partner 4
Live at home 5
Live on own 1
In supported accommodation 2
Parents of children 3
Have siblings 11
In full- or part-time education 5
Possess post-secondary qualiﬁcations 1
In full- or part-time employment 4
A journey of empowerment
Three participants described PT for HD as an empower-
ing experience, two carriers and one non-carrier. Katie
was particularly articulate about her journey of empow-
erment and the positive impact on her personal identity
and relationship with her partner.
Katie age 24, test at 21
Family background.Katie described having a ‘bad expe-
rience’ of HD when she was a child because she lived
with her affected mother and father who ‘never coped
with it’. There were issues of paternal non-disclosure and
concealment which meant that she had little knowledge
of HD or her risk until her mid teens. By then, Katie
was a young carer – looking after the household and her
siblings.
Deciding to test. In her late teens, Katie was increasingly
anxious about her risk, suffering from intrusive thoughts,
symptom searching and insomnia. She coped by being
‘constantly busy so not to think about it’ and now
believes she was ‘probably depressed’. Katie wanted the
test to make important life choices and future plans.
Experience of pre-test counselling. Katie chose to
proceed slowly with testing because she wanted time
to arrange her finances and be sure of her decision,
‘I wanted to take a while.’ Katie described a positive
experience of pre-test counselling:
I think they’re great people … It made me think about things you
wouldn’t think about on your own.
During this time, Katie also received support from
other agencies that she valued, especially advice from
the Huntington’s Association about end of life care, ‘I
was finding the visits [to mum] demanding and upset-
ting,’ and psychological support to cope with intrusive
thoughts.
Katie’s family had a tense relationship with the local
genetics service so she attended the majority of appoint-
ments alone. In addition, she chose not to tell her partner
about testing, or her family history, reflecting that ‘you’re
also doing your best so they don’t find out the real you’.
Post-testing.Katie described the difficulty of receiving a
carrier result and the time it took to adjust. A few months
afterwards she had a major ‘relapse’ about possible
symptoms and sought intervention from her counsellor,
who she felt understood and was quick to respond.
At the time of interview, Katie had implemented the
plans she had discussed in pre-test counselling and was
considering starting a family. She was hopeful about her
future and the possible benefits of clinical trials ‘in the
next 5–10 years’. She had also disclosed her result and
family history to her partner:
My partner he’s like you’re a different person now … And
thinking back to before the test I am. I’ve not really needed them
in the last year. I must be doing something right!
An ambivalent process
Four young women described seeking testing as more
ambivalent, reflecting they had mixed experiences,
one carrier, two non-carriers and one who postponed
testing. In these accounts, genetic counselling was
information-rich but there was a lack of emotional
support and little control over the test process.
Laura, age 18, testing postponed
Family background. Laura lives at home with her father
and mother who has late-stage HD. She was told about
her mum’s diagnosis by her parents as a child, noticing
the onset of symptoms around the age of 13/14. Laura
undertakes no personal care for her mother and there is
little interaction between them. Laura’s own risk was not
a huge concern for her until now.
Deciding to seek testing. Laura’s older sister recently
tested and received a non-carrier result, but this good
news ‘Just made me think my turn next! So I was
determined to get the test done as soon as I was 18’.
She searched for information online about HD, but found
different advice and ‘false hope’:
That was another reason why I was up for getting the test because
if it did come back positive there’d be medication … I thought I
wouldn’t change my mind at all.
Laura was encouraged to seek genetic counselling by
her family because ‘I was getting really worked up …
Everything was hitting me really hard about the disease’.
Experience of pre-test counselling. When Laura actu-
ally attended her appointment she was unsure whether
she would proceed with the test or not, ‘I was still 50/50
when I went in’. Laura valued the opportunity to receive
accurate information about HD and discuss the pros and
cons of testing – even though it was a shock to find out
there was no treatment, ‘It hit me really hard when they
said no there’s nothing’. And whilst Laura felt the infor-
mation was helpful, she also reflected that:
They never really looked into the emotional side of it, which is
the side I struggle with mostly … the everyday seeing my mum
and having that feeling I might get it … [It’s someone] to be there
for you … and understand the situation you’re going through …
[because] as soon as I go in there I just forget about the emotion.
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Postponing testing. Laura decided to postpone testing,
so she can concentrate on her short-term goals, i.e.
passing her exams. She does not want to ‘take the risk’
of getting bad news, questioning whether she would cope
‘with such a concrete answer’. She plans to seek help in
the future if she needs emotional support, e.g. through
online peer support or other counselling services.
Louise, age 18, test at 18
Family background. Louise is 18 years old and has a
daughter. She lives at home with her mother, stepfather,
daughter and other close relatives. Her parents separated
when she was a child. Louise has little contact with her
biological father. She only found out recently from her
mother about her estranged father’s family history of HD
and her own 50% risk.
Deciding to test. Whilst Louise ‘did not feel upset or
anything’ about this news, her reaction was to seek
testing and ‘go for it.’ She wants the test ‘for her
daughter’s sake’ because if she is a gene carrier she wants
to tell her daughter, but if she isn’t ‘she won’t have to go
through what I have’.
Experience of pre-test counselling. Louise finds wait-
ing ‘the worst feeling ever’ and would prefer to get
tested ‘straightaway and move on.’ She questioned why
there is so much emphasis on pre-test counselling instead
of post-testing. At the same time she acknowledged
‘it’s their job to make sure you’re ready.’ Louise com-
plies with three pre-test sessions, believing she needs to
present herself as ‘ready’ and to ‘speak up’ about why
she wants the test.
If she receives a bad result, Louise expects to be
‘devastated’, but her view, and that of her family’s, is
not to get ‘head over heels about it’. Whilst she has been
informed the average age of onset is late 30s/early 40s
Louise is adamant that she will not ‘speed things up’ and
plans to live her life ‘as I was going to do it’.
I’m not going to let it stop me from doing the things I want to do,
or the speed that I want to. I’m just going to do everything like I
normally do, as I was going to do it, and if it’s positive, when the
time comes, then fine! … I don’t want to speed things up … I
don’t want her being brought up in a rushed family … Just make
everything as normal as it can be.
Like others, Louise had not discussed her feelings with
her parents or siblings about testing, ‘we don’t really
speak about it’.
Post-testing. Louise found testing a long process, but
was not ‘going to back down’ and was relieved to get a
good result. In her post-test interview, Louise focused on
how she had become homeless during the test process
and the battle she had to find suitable housing. She
had recently secured her first home and stressed that
her priority was making a ‘normal family life’ with her
partner and daughter. Testing for HD had been one more
thing in a ‘busy stressful year’.
A poor experience
Five participants described testing for HD as a poor
experience, four carriers and one non-carrier. The ‘wait-
ing time’ was particularly anxious. Two young women
had not anticipated the extent to which their result
would impact on family dynamics and their own personal
identity.
Jenny, age 19, test at 18
Family background. Jenny grew up knowing about
HD because she was told by her parents as a child
and witnessed the illness in a close relative. In her
teens, Jenny’s mother was diagnosed with HD, but her
symptoms had little impact on family life. Her own risk
of HD was not a major concern. She felt she had a
close relationship with both parents and a ‘loving, open
family’.
Deciding to test. Prior to her 18th birthday, Jenny’s
mother had a sudden deterioration in her condition that
triggered a strong desire to test, ‘I couldn’t sit and watch
that and not know’. As soon as she turned 18, she sought
testing and believed she was a good candidate: she had
knowledge and experience of HD, a supportive family,
she was mature and would seek additional support.
Experience of pre-test counselling. Jenny was ‘rebel-
lious’ with her family and genetic counsellor and did not
seek her parents’ support, explaining that ‘I wanted to
talk about it every day, but I didn’t want to put it on mum
or dad’. Jenny also got involved with a new peer group
and began to engage in risky behaviour, admitting that ‘I
went off the rails for a bit … … I was taking my mind
off it all’. At the same time, she was preparing herself
to hear bad news, working with another professional to
consider the impact of testing:
Deep down, I convinced myself I had it. I structured my life
around it … for months … I was hard at it.
At her first visit, Jenny was informed that testing was
a long process but she was more sceptical than Louise
about the genetic counsellor’s role, ‘she only wants to
make sure I won’t commit suicide’, and less compliant:
I just kept going, can you just test me, can you just test me? I
don’t want to do this, I go through enough bloody counselling.
In this ‘year of firsts for everything’, Jenny had also
started her first serious intimate relationship, but realised
there was a pregnancy risk and decided she would
avoid sex.
Post-testing. A year later and Jenny is still reconciling
and adjusting to receiving a non-carrier result. She
described an ongoing messy personal life. And whilst
she continues to struggle with her mother’s worsening
condition Jenny has taken on a more caring role.
I’ve to stop being so doom and gloom about my mum, it’s not the
end of theworld …We’re losing her like … (voice quietens). But
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… everyday you’ve got to get up and … treat her like normal …
have a laugh … Everything is not going to go back to normal …
So it’s time I started dealing with that.
Jenny has also become her parents’ confidante, leading
to the discovery of a family secret that she had never
anticipated, and would not have been disclosed if she had
received a carrier result. Overall, Jenny reflected ‘It was
the worst year of my life’.
Michelle, age 19, test at 18
Family background.Michelle grew up in a single parent
family with her affected mother and sibling. She first
noticed changes in her mum in her early teens. They
found out it may be HD when a relative was diagnosed,
but her mother delayed diagnostic testing for several
years. Michelle disclosed a history of self-harm, but ‘is
getting help for that’.
Deciding to test. Previously, Michelle had not sought
testing because ‘we’ve always said we wouldn’t get
tested’. But she recently changed her mind, reflecting
that ‘I don’t do wait and see’. Michelle’s anxiety sig-
nificantly increased when she overheard relatives’ ques-
tion whether she was showing symptoms, ‘then I started
thinking about it all the time … So I wanted to get tested
… [to prove them wrong]’.
Pre-test counselling experience.Michelle was referred
for PT by a professional because of her anxiety, describ-
ing that ‘I got tested the weirdest way ever’ and how the
testing process was shortened:
My anxiety got too much, I ended up taking a bad turn, so they
were like I’ll give you your results asap because it’s not doing
you any good waiting.
She also chose not to tell any of her family about
testing – ‘I pushed them away … I didn’t want to
hurt them’. Michelle experienced another ‘bad turn’
several days before her result requiring professional
intervention, ‘I ended up flipping out and getting really
angry’.
Post-test experience. Similar to Katie, Michelle
described the profound emotional impact of being told
that she was a gene carrier, and that she had not expected,
or really prepared, to hear bad news.
Even though I did build myself up for it coming back positive I
still got really really emotional. And I didn’t expect it to come
back positive, deep down. And when it did … I didn’t want to
believe it at all.
Her initial reaction was shock and disbelief. She also
wanted to tell one of her relatives, ‘when I got the test
result back I was like I need to tell one of them’ and since
this disclosure some family relationships have improved.
Six months post-testing andMichelle is trying to adjust
to the bad news – ‘I still think I’m dealing with it’ – and
an additional dilemma that has emerged:
Just now I don’t know what to do … With the result I feel like I
need to do something quick, if that makes sense, because I know
that I am going to develop it … But just now I don’t really have
the motivation to do anything … [voice saddens and tails off] …
I don’t really know how much time I do have.
In retrospect, Michelle believes that she would have
coped better if she had had family support:
I think that I could’ve changed it because at the time I was
completely alone – I wasn’t because I had the staff – but I didn’t
have any family. And I feel like if I’d told them, or at least told my
gran, then I’d have been able to cope. I knew I had all the staff,
but it’s still not the same as your gran.
Discussion
This article explores YP’s experiences of PT for HD,
and is the first to document prospective and retrospective
accounts. A qualitative analysis was undertaken, which
revealed testing was experienced by YP as either: (1) a
journey of empowerment, (2) an ambivalent process, or
(3) a poor experience, regardless of test result.
A key finding was that a subgroup of YP experienced
the testing process and their result as empowering (9,11),
whether they received ‘good’ or ‘bad’ news. In partic-
ular, PT helped to establish personal identity – a key
developmental task at this age (17) – and could enable
disclosure in personal relationships, e.g. about being
a ‘pre-symptomatic’ person. We also found testing is
important for YP who have other identity challenges
related to HD, e.g. coming to terms with being adopted
or fostered, being a responsible young parent, or needing
to know if you will be a carer or patient. For participants
with ‘complex pasts’ (9), testing could be beneficial for
emotional regulation (19). It could also improve interper-
sonal and family relationships (10).
An important findingwas a subgroup ofYPwho sought
testing when a parent’s condition deteriorated, but the
emotional impact of losing a parent and living at risk
was ‘not looked into’. Previous research has found that
a significant minority of clinical genetics professionals
experience discomfort in the presence of grief and loss,
and also feel inadequately prepared for such patient
experiences (20). Taken together these findings suggest
there is a gap in pre-test counselling with regards to YP’s
experiences of grief and loss and any relation to seeking
testing.
In contrast to adult studies (21), the findings of the
present study draw attention to the isolation YP expe-
rience in pre- and post-testing and barriers to the devel-
opment of a trusting patient/counsellor relationship, e.g.
using defensive mechanisms such as rebellion or risky
behaviour (9). For many, this isolation was compounded
by a decision not to tell close relatives about test-
ing – either through a desire to protect them, poor rela-
tionships, or because testing went against the family
norm. Isolation during the test process may be partic-
ularly acute for YP who are likely to be separating
from parents, and experimenting with new but fragile
peer relationships (17), and concealment of risk was not
uncommon. An important finding is that in retrospect
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family support was preferred by participants, but it did
not have to be from direct family, or throughout thewhole
testing process. In contrast, a few YP found the support
person requirement prohibitive preferring to attend alone
(22), or felt there was an unhelpful duplication of ser-
vices.
The findings of the current study draw particular
attention to ‘The Waiting Period’ experienced prior to
receiving a test result (13), with participants describing
mild to severe anxiety.Whilst themajority felt this period
was too long, most complied with pre-test counselling.
However, similar to other studies of YP we found par-
ticipants ‘going through the motions’ or ‘playing a role’
to access testing (11). Participants also had different
pre-test experiences depending upon how and when they
had decided to seek testing. Like Macleod et al. (11) YP
who knew they wanted the test from their first appoint-
ment felt there was repetition and inflexibility. Thus, for
those who ‘have to know’ or ‘take the decision’ (23) we
support Macleod et al. who suggest that pre-test coun-
selling should focus more on the impact of the result,
rather than the advantages and disadvantages of testing.
In contrast, participants who were ‘evolving towards it’
(23), or who were undecided when they first attended,
wanted the opportunity to have these discussions – and
could change their mind about proceeding.
The waiting time was particularly stressful for YP
when they felt they did not have clear information about
how many pre-test appointments they were likely to
attend and the time span between each. In addition,
there was confusion when a YP expected the clinic to
contact them about appointments, but clinic practice was
for the YP to make contact. The data supports reports
that genetics professionals are cautious when counselling
YP for PT and may delay testing – using strategies
such as prolonging the length of the testing process and
waiting for YP to make contact (12). In contrast, we
also observed the detrimental impact of shortening the
recommended protocol. In either circumstance, if the
process became a ‘battle to get tested’ it added to distress
and had a negative impact on relationships (12).
The findings of the present study draw attention to
individuals who discover their family history ‘out of the
blue’ and seek testing straightaway. YP who received
good news in this category were able to adjust and
move on, but those receiving bad news found it hard
to cope, especially if they were living with a recently
diagnosed parent. In this subgroup, testing could also
be experienced as one more risk in a multitude of daily
challenges facing impoverished YP.
Like adult studies, YP who received results which con-
tradicted what they expected ‘deep down’ found it harder
to adjust (24), whether they were a carrier or non-carrier,
describing feelings of being stuck, lost and not know-
ing ‘what to do,’ similar to a mid-life or existential cri-
sis (9, 25, 26). As the majority of participants expressed
they ‘lived like gene-carriers’ there were complex con-
sequences of receiving a good result (6, 9). In contrast,
we also found YP who did not believe ‘deep down’ that
they were carriers – testing to ‘prove others wrong’ or
proceed with having children. Consequently, testing pos-
itive was unexpected and created more uncertainty (4, 9,
25) – and was a double bind if the YP had little psycho-
logical or material resources.
A final important finding was that some YP had
not anticipated the extent to which their result could
impact on family dynamics and family relationships.
In particular, how testing could lead to changes in
family roles such as becoming a young adult carer,
changes in family membership and changes in family
communication, e.g. who speaks to whom and levels of
openness (18). The complex and far reaching impact of
PT on family dynamics and family communication may
be another aspect that YP have little personal experience
of and find hard to anticipate.
Strengths and limits
A considerable strength of this study is that it reports
the retrospective and prospective experiences of YP who
have sought PT for HD. Offering a range of options
for taking part and recruiting through the Grampian
clinic and SHA meant we were able to recruit more
diverse participants – including YP who were candid
about their adjustment difficulties. A limit of the study
is that we only identified three young men to invite,
Table 2. Implications for practice
• As well as testing YP may be seeking support to deal with emotions such as anger, intrusive thoughts or grief and loss. Refer
elsewhere if necessary, e.g. Huntington’s Association, Psychology or Peer Support.
• Explore understanding of potential impact on family dynamics and family communication whether receive a carrier or non-carrier
result.
• Explore YP’s beliefs about their genetic status and discuss potential impact of an unexpected result.
• Discuss whether testing will help or hinder in dealing with identity issues, such as becoming a carer or becoming
pre-symptomatic, being adopted or fostered, being a responsible parent.
• Encourage use of available family support before and after testing, this need not be through nuclear family e.g. aunt or uncle,
grandparents, cousins.
• Avoid duplication of services if young person also receiving support elsewhere.
• Be clear about whose responsibility it is to make further appointments i.e. the young person or clinic.
• Provide clear and engaging written and verbal information about PT protocol, especially number of pre-test appointments and
time span between each – signpost to resources such as HDYO www.hdyo.org.
• Consider if it at increased risk of crisis in time between venepuncture and result and facilitate additional support or intervention.
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none of whom wanted to take part, even though similar
numbers of young men and young women access testing
in the UK (27). Future studies should explore any
differences in adjustment related to gender and age,
e.g. between mature adolescents and young adults in
their 20s. Future research is also needed to explore
the long-term outcomes for YP who seek PT for HD
and any interventions that might help gene carriers in
the intervening years before diagnosis. We outline key
recommendations for practice in Table 2.
Conclusions
Whilst YP’s experiences of PT forHD are generally simi-
lar to those of adults, testing helped or interfered with key
issues related to this age and stage, e.g. establishment of
personal identity, separation from parents and the devel-
opment of peer/intimate relationships. Most YP felt that
the pre-test period was too long but those who had clear
and engaging information about the PT protocol and the
likely number and interval between appointments coped
better. YP who were separating from parents and/or had
traumatic experiences of growing up with HD could be
very isolated during the test process. If YP sought testing
when a parent’s condition had significantly declined, the
impact of grief and loss may need additional considera-
tion. In the post-test period, the most vulnerable YP were
those who had received results which contradicted what
they felt ‘deep down’, and those who did not anticipate
the impact testing could have on family dynamics. Future
research is needed to explore the long term outcomes for
YP who seek PT for HD and any interventions that might
help in the post-test period.
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